Skip to content
Subscriber Only

Ex-FDA Chief Says J&J Knew Drug Linked to Male Breast Growth

Updated on

Johnson & Johnson, which paid more than $2 billion to resolve a criminal probe over its antipsychotic drug Risperdal, knew as early as 2001 that the medication caused boys to grow breasts, a former government regulator said in the first case over the treatment set to be decided by a jury.

Officials of J&J’s Janssen unit funded a 2001 study that showed 3.8 percent of boys given Risperdal during the clinical trial developed breasts that were either “probably or very likely” caused by the drug, David Kessler, the former head of the U.S. Food and Drug Administration, testified Wednesday in state court in Philadelphia.